The effect of valerian on cognitive disorders in hemodialysis' patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201606076318N7

Enrollment

Registered

2016-06-17

Start date

2016-05-26

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis patients. Dementia in other specified diseases classified elsewhere

Interventions

Intervention 1: Group A uses Valerian capsules (Sedamin 530 mg, Goldaru Co.) 60 minutes before bedtime for one month. After one month (cleaning or wash out), the type of treatment between two groups i

Group A uses Valerian capsules (Sedamin 530 mg, Goldaru Co.) 60 minutes before bedtime for one month. After one month (cleaning or wash out), the type of treatment between two groups is replaced, grou

Group B uses placebo capsules (starch 50 mg, Goldaru Co.) 60 minutes before bedtime for one month. After one month (cleaning or wash out), the type of treatment between two groups is replaced, group B

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Over 18 years of age; hemodialysis 3 times a week for 3 hours; for more than 3 months; full consciousness; hearing and speech ability; and not having sensitivity to plants. Exclusion criteria: Physical or mental disability; drug abuse; cancer; hearing or visual disorder; experienced recent stressful event; kidney transplant; acute illness; body mass index over 30; liver disease; hepatitis; cirrhosis; travel; or death of the patient.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Cognitive status. Timepoint: Before the intervention, one month after the first intervention, one month after the cleansing and one month after the second intervention. Method of measurement: In this study, Cognitive status is measured by using Electroencephalography (EEG) and MMSE questionnaire. This measurement is performed within three consecutive months (before the intervention, one month after the first intervention, one month after the cleansing and one month after the second intervention). The score for total cognitive health is (25-30), for mild cognitive disorder is (21-24), for moderate disorder is (10-20) and for severe disorder is (<9). Information for each person will be recorded in their personal questionnaire.	—

Measure

Time frame

Cognitive status. Timepoint: Before the intervention, one month after the first intervention, one month after the cleansing and one month after the second intervention. Method of measurement: In this study, Cognitive status is measured by using Electroencephalography (EEG) and MMSE questionnaire. This measurement is performed within three consecutive months (before the intervention, one month after the first intervention, one month after the cleansing and one month after the second intervention). The score for total cognitive health is (25-30), for mild cognitive disorder is (21-24), for moderate disorder is (10-20) and for severe disorder is (<9). Information for each person will be recorded in their personal questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMonir Nobahar

Semnan University of Medical Sciences

nobahar43@semums.ac.ir; Nobahar43@yahoo.com+98 23 3365 4170

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 4, 2026